FindTrial
Sign In

Retrospective Study on Gold Nanocomposites for NMIBC Bladder Perfusion Diagnosis and Treatment

Retrospective Study on Gold Nanocomposites for NMIBC Bladder Perfusion Diagnosis and Treatment

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600118388
Enrollment
Unknown
Registered
2026-02-04
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-02-09

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bladder cancer

Interventions

Trail group:NA

Sponsors

Sun Yat-sen University Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Age >18 years; 2. Undergo surgery for the first time; 3. Pathologically diagnosed with non-muscle-invasive bladder cancer.

Exclusion criteria

Exclusion criteria: 1. Age <18 years; 2. Secondary surgery; 3. Patients with concurrent or subsequent other malignancies within 5 years prior to admission.

Design outcomes

Primary

MeasureTime frame
HER2 score;AuNS@DV organization signal;—

Countries

China

Contacts

Public ContactJiang Yang

Sun Yat-sen University Cancer Center

yangjiang@sysucc.org.cn+86 20 39336609

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 15, 2026